Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms, Plasma Cell 3Myasthenia Gravis 3Neoplasms 2Lymphoma 2Leukemia 2Infections 2Neuromyelitis Optica 1Myelitis, Transverse 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Limbic Encephalitis 1Immunoglobulin Light-chain Amyloidosis 1Epilepsy 1Epilepsies, Partial 1Drug Resistant Epilepsy 1Autoimmune Diseases of the Nervous System 1Autoimmune Diseases 1

Interventions

fludarabine 2Cyclophosphamide 2thymoglobulin 1prednylidene 1ofatumumab 1deltacortene 1daratumumab 1carmustine, poliferprosan 20 drug combination 1Telemedicine 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Mitoxantrone 1Melphalan 1Immunologic Tests 1Immunoglobulins, Intravenous 1Etoposide 1Data Collection 1Cytarabine 1Carmustine 1Blood Specimen Collection 1Antilymphocyte Serum 1Alleles 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Autoimmune Diseases of the Nervous System × Immunoglobulins, Intravenous × Clear all
NCT01545518 2014-09-01

IVIG Treatment for Refractory Immune-Related Adult Epilepsy

Emory University

Phase 2 Terminated
20 enrolled 3 charts

Drug Resistant Epilepsy, Autoimmune Diseases, Epilepsy, Epilepsies, Partial, Autoimmune Diseases of the Nervous System, Limbic Encephalitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡